← Leaderboards
Sandra P D'angelo
Sloan-Kettering Inst Can Research
$2,079,738
Attributed
$2,079,738
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $625.7K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
FDA$2,079,738 · 1
By mechanism
R01$2,079,738 · 1
Top collaborators
No co-investigators on record.
Grant awards (4)
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma$625,681
R01 · FY2025 · FD · contact PI
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma$620,672
R01 · FY2024 · FD · contact PI
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma$615,811
R01 · FY2023 · FD · contact PI
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma$217,574
R01 · FY2022 · FD · contact PI